- Ziopharm Oncology, Inc. is a non-revenue-producing early clinical-stage biopharmaceutical company aiming to develop or acquire immuno-oncology therapies.
- Ziopharm's current product candidates include TCR+T therapies targeting solid tumors, CAR-T therapies targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 plus veledimex for regulating IL-12 production treating adult glioblastoma multiforme.
- Ziopharm is in a pretty weak financial position with cash of $100M, but with a high cash burn of -$72M (TTM ended March 2021) highlighting only 1.38 years of cash burn.
- Ziopharm has yet to present sufficient data to better understand the therapeutic potential they offer, but the company has seemingly been evasive with its current progress to date.
- In summary, the author projects Ziopharm Oncology, Inc. as a "hold" until Dec. 2021 when further clinical data is provided.
For further details see:
Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies